![Screenshot of the title slide of the webinar against a white backdrop. At the top the title reads "Immune responses to cancer immunotherapy outside the tumor." Below is an illustrated infographic showing a human and mouse, a section of the mouse is encircled and zoomed out to show multiple tissues (bone, spleen, lymph node, lung), and the a section of the spleen is encircled and zooms out to show many types of immune cells in difference colors (DCs, T cells, macrophages, neutrophils). At the bottom are the logos of four institutions: UCSF, Gladstone, PICI, and Chan-Zuckerberg Biohub. In a small circle the bottom right corner is a preview of Matt's headshot-style recording.](https://teiko.bio/wp-content/uploads/2023/03/Matt-Webinar-Thumbnail.png)
Video Webinar: Immune responses to cancer immunotherapy outside the tumor
Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar.
Reference citation: Kovacsovics-Bankowski M, Sweere JM, et al. Decreased frequencies of suppressive regulatory T cells and higher frequencies of naïve CD4+ T cells in peripheral blood at baseline are associated with severe immune-related adverse events and clinical benefit in checkpoint inhibitor-treated melanoma. 2023. The 20th International Congress of the Society for Melanoma Research.